Last updated: July 30, 2026
Cardizem SR is an extended-release formulation of diltiazem hydrochloride, a nondihydropyridine calcium-channel blocker used primarily for hypertension and chronic stable angina. The branded product has no meaningful current clinical-trial program, no active development pipeline, and limited standalone commercial relevance. Market demand has shifted to generic diltiazem extended-release capsules, tablets, and other modified-release products. Future revenue is likely to remain stable to declining in mature markets, with competition driven by price, supply reliability, dosage-form substitution, and institutional purchasing.
What is Cardizem SR and how does it work?
Cardizem SR contains diltiazem hydrochloride in a sustained-release oral dosage form. Diltiazem inhibits calcium influx through L-type calcium channels in cardiac and vascular smooth muscle. Its pharmacologic effects include:
- Reduced myocardial oxygen demand
- Lower systemic vascular resistance
- Slowed atrioventricular-node conduction
- Reduced heart rate in susceptible patients
- Increased coronary blood flow
The U.S. product labeling for Cardizem SR identifies hypertension and chronic stable angina as indications. Cardizem SR is distinct from Cardizem CD and Cardizem LA, which use different extended-release technologies, dosing schedules, and product approvals. These products should not be treated as automatically interchangeable solely because they contain the same active ingredient. (FDA, 2024a)
Cardizem SR dosage form
Cardizem SR is an oral sustained-release capsule formulation. Diltiazem is also marketed in several other dosage forms:
| Product category |
Typical dosage form |
Main commercial role |
| Cardizem SR |
Sustained-release capsule |
Historical branded oral product |
| Generic diltiazem ER |
Extended-release capsule or tablet |
Current primary oral market |
| Cardizem CD |
Once-daily extended-release capsule |
Separate branded formulation |
| Cardizem LA |
Extended-release tablet |
Separate branded formulation |
| Generic immediate-release diltiazem |
Tablet or capsule |
Hypertension, angina, rate-control use |
| Injectable diltiazem |
Intravenous solution |
Acute atrial fibrillation/flutter rate control and certain tachyarrhythmias |
What clinical trials have evaluated Cardizem SR?
Cardizem SR does not have a current brand-specific clinical development program. The product’s clinical evidence comes primarily from historical hypertension and angina studies supporting diltiazem and sustained-release diltiazem formulations.
The evidence base for diltiazem includes:
- Blood-pressure reduction in patients with mild-to-moderate hypertension.
- Reduction in anginal frequency and improvement in exercise tolerance.
- Ventricular-rate control in atrial fibrillation and atrial flutter, mainly through immediate-release or intravenous formulations.
- Pharmacokinetic studies comparing sustained-release products with immediate-release diltiazem.
- Postmarketing safety data covering bradycardia, hypotension, conduction abnormalities, edema, and drug interactions.
Cardizem SR itself is not a prominent intervention in modern interventional trials. Contemporary clinical research generally evaluates diltiazem as a background drug, comparator, or rate-control therapy rather than as a branded Cardizem SR product.
What is the current ClinicalTrials.gov status?
There is no material active trial program identified for Cardizem SR as a branded investigational product. Searches for diltiazem produce studies involving atrial fibrillation, supraventricular tachycardia, hypertension, migraine, coronary disease, and procedural care, but these studies do not represent new clinical development for Cardizem SR.
The distinction matters commercially. A study involving generic diltiazem or intravenous diltiazem does not create new exclusivity for Cardizem SR and does not support a new branded indication unless the sponsor completes the required regulatory program and obtains FDA approval.
What is the FDA regulatory status of Cardizem SR?
Cardizem SR was approved as a prescription extended-release diltiazem product. Its regulatory position is now primarily historical because generic diltiazem extended-release products have replaced the branded product in routine prescribing.
The FDA regulatory framework treats each extended-release formulation as a separate product for approval and substitution purposes. Cardizem SR, Cardizem CD, Cardizem LA, and generic extended-release products can differ in:
- Release mechanism
- Pharmacokinetic profile
- Dosing frequency
- Capsule or tablet design
- FDA application
- Approved labeling
- Substitution status
The FDA Orange Book identifies approved multisource products and their therapeutic-equivalence ratings. A generic diltiazem ER product must demonstrate pharmaceutical equivalence and bioequivalence to its reference product or obtain approval through another legally recognized pathway. (FDA, 2024b)
Is Cardizem SR currently marketed?
Cardizem SR has limited or no material current U.S. branded-market presence compared with generic diltiazem ER. Historical product availability does not establish current commercial marketing. FDA product databases can list discontinued or no-longer-marketed products even when the brand is absent from pharmacy distribution.
The practical market is therefore divided between:
- Generic diltiazem ER products
- Other branded diltiazem formulations
- Generic immediate-release diltiazem
- Intravenous diltiazem
- Alternative rate-control and antihypertensive therapies
What patents protect Cardizem SR?
Cardizem SR does not have a commercially relevant active patent estate that would block ordinary generic competition. The original composition, formulation, and product-specific patent protections are historical. Any original U.S. patents associated with diltiazem or early sustained-release formulations would have expired well before the current period.
The principal intellectual-property barriers were historically associated with:
- Diltiazem active-ingredient claims
- Sustained-release dosage forms
- Release-rate control
- Capsule or bead technology
- Pharmacokinetic performance
- Manufacturing processes
Those barriers no longer provide meaningful market exclusivity for the original Cardizem SR product.
Are there Orange Book patents for Cardizem SR?
No current Orange Book patent barrier is expected to prevent generic diltiazem ER competition for the historical Cardizem SR product. Orange Book listings can change as products are discontinued, delisted, or transferred between sponsors. The absence of a current enforceable patent barrier is consistent with the long-established generic market.
Patent analysis should distinguish Cardizem SR from later diltiazem products. A patent covering a later once-daily formulation, multiparticulate system, or specific release profile would not automatically protect Cardizem SR.
Were there Paragraph IV challenges?
Generic applicants historically could have challenged any listed patents associated with diltiazem extended-release products through Paragraph IV certifications. Those challenges are no longer a significant commercial issue for Cardizem SR because the original market exclusivity period and relevant patent terms have expired.
Current generic risk is therefore operational rather than litigation-based. Key risks include:
- Product shortages
- FDA manufacturing observations
- API supply disruption
- Recalls
- Contract-manufacturing changes
- Reimbursement pressure
- Formulation-specific substitution limits
When did Cardizem SR lose exclusivity?
Cardizem SR lost effective market exclusivity years ago. The original diltiazem molecule was discovered and commercialized decades before the current generic market. The relevant exclusivity periods consisted of:
| Exclusivity type |
Current position |
| New chemical entity exclusivity |
Expired |
| Original product patent protection |
Expired |
| Formulation patents |
Historical or expired for the original SR product |
| Pediatric exclusivity |
No material current effect |
| Orphan exclusivity |
Not applicable |
| Current regulatory exclusivity |
None of commercial significance |
FDA approval of generic diltiazem extended-release products confirms that the market is open to multisource competition. (FDA, 2024b)
How strong is the Cardizem SR patent estate?
The Cardizem SR patent estate is weak from a current commercial-protection perspective. Its historical value was based on formulation differentiation rather than an enduring active-ingredient monopoly. The key strength indicators are:
| Factor |
Assessment |
| Active compound protection |
None |
| Current formulation exclusivity |
None of material commercial effect |
| Generic blocking position |
Weak |
| Litigation leverage |
Low |
| Manufacturing know-how value |
Moderate but product-specific |
| Brand pricing power |
Low |
| Lifecycle-management value |
Limited |
The remaining technical value lies in manufacturing consistency, dissolution performance, stability, and supply-chain execution. Those attributes can support a supplier relationship but generally do not create a durable legal barrier to generic entry.
What is the Cardizem SR market size?
Cardizem SR does not have a reliable standalone market category in public pharmaceutical reporting. Most datasets aggregate it with generic diltiazem extended-release products or with the broader diltiazem market. Public company filings typically do not report Cardizem SR revenue separately.
The commercial market is best analyzed through prescription volume, not brand revenue. Diltiazem remains an established low-cost cardiovascular medicine, but its value has declined because of:
- Generic substitution
- Therapeutic competition
- Limited innovation
- Low reimbursement rates
- Multiple approved dosage forms
- Retail and hospital purchasing concentration
The largest commercial opportunity is not the legacy brand. It is reliable supply of generic extended-release diltiazem, particularly where competitors experience shortages or manufacturing disruptions.
What companies compete with Cardizem SR?
Competition comes from generic manufacturers and alternative cardiovascular products. Depending on dosage form and market, generic diltiazem suppliers may include large manufacturers such as Teva, Viatris, Sandoz, Hikma, Amneal, and other FDA-approved applicants. Supplier participation varies by strength, formulation, market, and time.
Therapeutic competitors include:
- Verapamil
- Beta blockers such as metoprolol and atenolol
- Dihydropyridine calcium-channel blockers such as amlodipine
- Digoxin for selected rate-control settings
- Antiarrhythmic therapies in defined patient populations
Diltiazem has a differentiated role in patients needing both rate control and vasodilatory activity. That clinical utility supports continuing demand even though it does not support premium pricing.
What is the revenue outlook for Cardizem SR?
The standalone Cardizem SR revenue outlook is limited. A practical forecast should assume that branded sales remain negligible unless a sponsor relaunches the product with a new commercial strategy.
Base-case market projection
| Period |
Cardizem SR branded outlook |
Generic diltiazem ER outlook |
Principal driver |
| 2025-2026 |
Flat to declining from a low base |
Stable to modestly declining |
Mature generic demand |
| 2027-2029 |
Minimal branded contribution |
Low-single-digit volume pressure |
Price erosion and substitution |
| 2030 onward |
No material growth expected |
Stable essential-use demand |
Aging cardiovascular population offset by generic erosion |
A relaunch could produce limited niche revenue through improved supply, packaging, or a differentiated delivery profile. It would face substantial barriers:
- No meaningful patent protection
- Low physician switching incentive
- Generic price competition
- Pharmacy substitution
- Limited promotional return
- Need for dependable manufacturing scale
The broader diltiazem market should remain resilient because hypertension, coronary disease, atrial fibrillation, and supraventricular tachycardia continue to generate demand. Volume stability will not necessarily translate into revenue growth.
What generic launch scenarios exist for Cardizem SR?
Scenario 1: Continued generic erosion
This is the most likely scenario. Multiple generic suppliers maintain supply, prices remain low, and the Cardizem SR brand has little commercial role.
Scenario 2: Supply-constrained pricing
A manufacturing disruption or shortage among major suppliers could temporarily increase contract prices or improve the economics of smaller suppliers. The effect would likely be temporary because diltiazem is an established molecule with broad manufacturing experience.
Scenario 3: Formulation-specific substitution limits
A generic product may be therapeutically equivalent to one reference extended-release product but not automatically substitutable for every diltiazem modified-release formulation. This creates narrow opportunities for formulation-specific products with validated pharmacokinetic characteristics.
Scenario 4: Brand relaunch
A relaunch would require commercial differentiation, dependable supply, and a reimbursement strategy. Patent-based protection would not be the principal value driver.
What manufacturing and IP barriers affect diltiazem ER?
Manufacturing barriers are higher than the legal barriers. Extended-release diltiazem requires controlled release over the intended dosing interval and consistent dissolution across production lots. Regulatory risks include:
- Dissolution-profile failure
- Dose dumping
- Batch-to-batch variability
- Capsule-fill variation
- Stability problems
- API impurity control
- Packaging-related degradation
- Inadequate process validation
A sponsor with strong modified-release manufacturing capabilities can compete despite low margins. The commercial advantage comes from quality and supply continuity rather than exclusivity.
How does Cardizem SR compare with Cardizem CD and Cardizem LA?
| Attribute |
Cardizem SR |
Cardizem CD |
Cardizem LA |
| Active ingredient |
Diltiazem HCl |
Diltiazem HCl |
Diltiazem HCl |
| Release design |
Sustained release |
Extended release |
Long-acting extended release |
| Dosing profile |
Product-specific |
Generally once daily |
Generally once daily |
| Patent position |
Historical, expired |
Historical or formulation-specific |
Historical or formulation-specific |
| Generic competition |
Established |
Established |
Established or formulation-specific |
| Current commercial position |
Limited |
Brand and generic legacy presence |
Brand and generic legacy presence |
| Substitution |
Depends on FDA rating and product |
Depends on FDA rating and product |
Depends on FDA rating and product |
These products should not be evaluated as one interchangeable patent or market category. A formulation-specific patent could protect a later product without restoring protection to Cardizem SR.
What litigation and settlement agreements affect Cardizem SR?
No active litigation or settlement agreement is expected to have a material effect on the current Cardizem SR market. Historical patent disputes involving diltiazem extended-release products may have affected the timing of generic entry, but those disputes no longer determine current market access.
The relevant current legal issues are more likely to involve:
- FDA approval disputes
- ANDA deficiencies
- Product liability
- Manufacturing compliance
- Drug-shortage allocation
- Contract disputes
- Trademark use for discontinued brands
Key Takeaways
- Cardizem SR is an older sustained-release diltiazem product with limited current branded-market relevance.
- No meaningful active clinical-trial program is associated with Cardizem SR.
- The product’s historical patents and regulatory exclusivities have expired.
- Generic diltiazem extended-release products define the current market.
- Standalone Cardizem SR revenue is likely negligible and has limited growth potential.
- Future commercial value depends on manufacturing reliability, formulation quality, and supply continuity.
- Diltiazem demand should remain clinically durable, but generic pricing will constrain revenue.
- Cardizem SR, Cardizem CD, and Cardizem LA have different release technologies and should not be assumed to be automatically substitutable.
- Current competitive risk is operational and pricing-based rather than patent-litigation-based.
FAQs
Is Cardizem SR still available by prescription?
The original branded product has limited current availability. Prescribers generally use generic diltiazem extended-release products or other approved diltiazem formulations.
Is generic diltiazem SR equivalent to Cardizem SR?
Equivalence depends on the specific FDA-approved reference product, dosage strength, release technology, and Orange Book therapeutic-equivalence rating. Extended-release diltiazem products should not be substituted solely on the basis of active ingredient.
Does Cardizem SR have a patent expiration date?
Any original patents associated with Cardizem SR are historical and expired. No current patent term is expected to block generic diltiazem extended-release competition.
Is diltiazem being studied for new indications?
Diltiazem continues to appear in clinical studies and treatment protocols, particularly in arrhythmia and cardiovascular settings. Those studies generally do not represent new branded development for Cardizem SR.
What is the investment case for diltiazem extended-release manufacturing?
The investment case is based on stable essential-use demand and supply reliability, not patent exclusivity. Returns depend on manufacturing cost, regulatory performance, customer concentration, product availability, and the ability to avoid commodity-level price competition.
References
-
U.S. Food and Drug Administration. (2024a). Cardizem SR: Prescribing information. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024c). Drugs@FDA: FDA-approved drug products. FDA.
-
National Library of Medicine. (2024). ClinicalTrials.gov search results for diltiazem. U.S. National Library of Medicine.
-
American College of Cardiology, American Heart Association, and Heart Rhythm Society. (2019). 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation, 140(6), e285-e292.
